Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Pharmaceuticals Group PLC

http://www.shire.com

Latest From Shire Pharmaceuticals Group PLC

Accelerated Approval Price Trends Show Sponsors Can ‘Lose But Not Win’ From Confirmatory Trials

Study drills down into the lack of economic incentives for conducting confirmatory studies to inform policies that could remedy to the situation.

Pricing Debate Review Pathway

Genfit To Pick Up Second Liver Failure Candidate In €40m Versantis Buyout

Focused on rare liver diseases such as acute-on-chronic liver failure following its 2020 disappointment in NASH, Genfit looks to become sector leader in ACLF and other indications such as hepatic encephalopathy.

M & A Deals

Lupin Liquidating Japan JV With Yoshindo, Partners With I’Rom For Denosumab Biosimilar

Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.

Strategy Deals

Lupin Liquidating Japan JV With Yoshindo, Partners I’Rom For Denosumab Biosimilar

Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.

Commercial Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Advanced BioHealing, Inc. (renamed Shire Regenerative Medicine)
    • AesRX LLC
    • Baxalta Incorporated
    • BIKAM Pharmaceuticals Inc.
    • Chatham Therapeutics
    • Dyax Corp.
    • FerroKin BioSciences, Inc.
    • Fibrotech Therapeutics
    • Foresight Biotherapeutics Inc.
    • Gambro AB
    • Immuno-US
    • Jerini AG
    • Lotus Tissue Repair
    • Lumena Pharmaceuticals
    • Meritage Pharma, Inc.
    • Movetis NV
    • New Pervasis Therapeutics, Inc.
    • NPS Pharmaceuticals, Inc.
    • Premacure AB
    • Prism Pharmaceuticals, Inc.
    • River Pharmaceuticals
    • Roberts Pharmaceutical Corporation
    • SARcode Corporation
    • SuppreMol GmbH
    • Synovis Life Technologies, Inc.
    • Transkaryotic Therapies, Inc.
    • ViroPharma Inc.
UsernamePublicRestriction

Register